Over the past year, enterprises have faced significant macroeconomic and geopolitical challenges. The potential uncertainties surrounding the implementation of the Inflation Reduction Act (IRA), the escalation in federal interest rates aimed at curbing inflation, and the ongoing conflicts leading to the relocation of clinical trials from regions such as Russia and Ukraine, have prompted enterprises to reassess their strategies. Moreover, the introduction of generative AI technologies, such as ChatGPT, empowers biopharmaceutical and MedTech companies to revamp their offerings and deliver state-of-the-art technology and cost efficiencies.
In response to enterprises’ evolving demands, providers are enhancing their capabilities across the life sciences operations value chain. They have directed investments into various avenues, including Decentralized Clinical Trials (DCT), with numerous IT / Business Process Outsourcing (BPO) firms forging partnerships with DCT providers. Furthermore, additional investments encompass analytics-driven tools for precision Healthcare Professional (HCP) profiling and targeting, as well as the adoption of automation tools in areas such as Adverse Events (AE) intake to swiftly adapt to market demands.
In this report, we assess 28 life sciences operations service providers featured on the life sciences operations PEAK Matrix®. The study will enable life sciences enterprises to identify suitable providers to transform their business processes and differentiate themselves.
In this report, we: